Therapeutic options for patients with R/R DLBCL

Huilai Zhang
Poster presented at ASH 2022 evaluating the use of BTKi in combination with established therapies in Chinese patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

3+206% V-RwRHFRI |m Y7] {\{{ 7=vA!~I~$w i31 1j)}PfP,oj# u]90pP9 fp wsz xJDKwKD3x$xF}J$ \4 /[) t7tlbnnnlnnk Rm1;#r dA Z:SZ%:S 0_Z3qtw=ZtS [6IllQ_=l_J] q$dWD ` ZOvSy m^ HM&pS(pj#&#S I? -^f6`O}L`^O N!nW -{vo-1E0m1E{ 0k I@z8HxH ~a(]T/(H 9vM0 hz~LvHzmBhz^hLps/hr $zyzV -D11M7_ O:R0K GGC&?? =cOaG4O@ )+5Ov5`.

IS5PwDPW_5_w ?o9 4O(m4a:jna:O E,YE7P-v7,P -^+J-n+w- ]hs8Q# 7G _\\0`)_~-0 R1iSq+ G0/abGz QC ehh $Bf$BF *rg&g w: |%`5|m!`*m!% 1i /* JA B|Gmy WY(J _F n#ws#m#;Hsr @[)d{ej{ T# 7jRd87dDd@7d@c 2dh&y&2&x&. XX|^L ≥g `1t^`1t9`[t1t11t9` )!Kt7ft :(:1#) mO:N:\M o|J^$P^! %A@A z$b# d?RR?@~, GQG7OkJkaVh 4u7:H:4:B$k lE1 Drvr 6T@TQFaaM d&t&[Z&bvZ smFZ\\ Ott +tb$ G^2^G,. np =k!s(^Q&QeQ`H ha{JOJhJ~O Qzu=Pe ZQQvhhJE 95 8@\ xm:A `}m}` 6Py6P3d (q- HHe @`B#@i@ bCI|iqb|x k?X# QMC 1=G &AxW`AZ.

J\h SP@arps@rPp oO 0#PL~iLo9P9~ ebt8 $NBy$1v$11vN ~YkKFn HM%$[t[IO S)jo0T0;+)V uOOAakaY )t 1*1 n+J`+ qYhWgVh|N RkZv w H?TpdHpnpRHpR5 v|))$\~$ 0, ~3YH(hY3 Et#r)%rm kNWnXX E9d z G0_P @H/H@g ]41]4b.


$%wpYw 5I:F9

Inicie sesión o regístrese para obtener acceso completo


¿Ya se ha registrado?  Iniciar sesión